"10925"^^ . . . . . . . . . . "11662"^^ . "1"^^ . . . . . . . . . . "Jednor\u00E1zov\u00E9 d\u00E1vky antacida (hydroxid ho\u0159e\u010Dnat\u00FD/hydroxid hlinit\u00FD) nem\u011Bly na biologickou dostupnost sildenafilu vliv.\nA\u010Dkoli nebyly provedeny specifick\u00E9 interak\u010Dn\u00ED studie pro v\u0161echny l\u00E9\u010Div\u00E9 p\u0159\u00EDpravky, popula\u010Dn\u00ED farmakokinetick\u00E1 anal\u00FDza neprok\u00E1zala \u017E\u00E1dn\u00FD \u00FA\u010Dinek sou\u010Dasn\u011B pod\u00E1v\u00E1n\u00FDch l\u00E9k\u016F na farmakokinetiku sildenafilu, pokud se uva\u017Eovaly skupiny l\u00E9k\u016F jako inhibitory CYP2C9 (nap\u0159. tolbutamid, warfarin, fenytoin), inhibitory CYP2D6 (nap\u0159. selektivn\u00ED inhibitory zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu, tricyklick\u00E1 antidepresiva), thiazid a p\u0159\u00EDbuzn\u00E1 diuretika, kli\u010Dkov\u00E1 a drasl\u00EDk \u0161et\u0159\u00EDc\u00ED diuretika, ACE inhibitory, blok\u00E1tory kalciov\u00FDch kan\u00E1l\u016F, antagonist\u00E9 beta-adrenoreceptor\u016F nebo induktory metabolismu CYP-450 (jako nap\u0159. rifampicin, barbitur\u00E1ty)."@cs . . . . .